BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 20209485)

  • 1. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.
    Ide LM; Iwakoshi NN; Gangadharan B; Jobe S; Moot R; McCarty D; Doering CB; Spencer HT
    J Gene Med; 2010 Apr; 12(4):333-44. PubMed ID: 20209485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.
    Ide LM; Gangadharan B; Chiang KY; Doering CB; Spencer HT
    Blood; 2007 Oct; 110(8):2855-63. PubMed ID: 17569821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
    Moayeri M; Hawley TS; Hawley RG
    Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
    Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
    Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
    Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
    J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.
    Gangadharan B; Parker ET; Ide LM; Spencer HT; Doering CB
    Blood; 2006 May; 107(10):3859-64. PubMed ID: 16449528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
    Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
    Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
    Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
    Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
    Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
    J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A.
    Kumar P; Gao K; Wang C; Pivetti C; Lankford L; Farmer D; Wang A
    Cell Transplant; 2018 Jan; 27(1):130-139. PubMed ID: 29562772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
    Moayeri M; Ramezani A; Morgan RA; Hawley TS; Hawley RG
    Mol Ther; 2004 Nov; 10(5):892-902. PubMed ID: 15509507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of murine hemophilia A following nonmyeloablative transplantation of hematopoietic stem cells engineered to encode an enhanced human factor VIII variant using a safety-augmented retroviral vector.
    Ramezani A; Hawley RG
    Blood; 2009 Jul; 114(3):526-34. PubMed ID: 19470695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
    Tiede A; Eder M; von Depka M; Battmer K; Luther S; Kiem HP; Ganser A; Scherr M
    Gene Ther; 2003 Oct; 10(22):1917-25. PubMed ID: 14502221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
    Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
    Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
    Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
    Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC; Scott DW
    Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.